Shares of CVS Health plunged roughly 10% in pre-market trading to $93.97 on August 7, despite the company posting a second-quarter earnings and revenue beat and lifting its full-year 2026 adjusted EPS guidance to $7.20–$7.35. The sell-off signals that Wall Street is looking past near-term results and pricing in deeper anxieties about the health insurer's cost trajectory. CVS Crushes Earnings and Hikes Guidance, But Wall Street Sees Storm Clouds in 2027 — Is the Turnaround Already Priced In?
Shares of CVS Health cratered as much as 10.4% on Wednesday, even after the company delivered a blockbuster second quarter that beat forecasts on virtually every line. CVS reported adjusted earnings of $2.58 per share, crushing the consensus estimate of $1.87 by $0.71.
Revenue climbed 7.3% year over year to $106.1 billion, also well above expectations. The paradox — a sell-off after a massive beat — reveals investors are already looking past 2026 and worrying about what comes next.
A Blowout Quarter Meets a Skeptical Market. CVS raised its full-year 2026 adjusted EPS guidance by $0.60 to a range of $7.90–$8.10 , and now expects revenue of at least $414 billion, up from a prior outlook of $405 billion.
Aetna's insurance margin recovery drove over $2 billion in year-over-year profit improvement in the first half alone. Yet the stock still sold off — a classic case of investors deciding the good news was already baked into the share price.
The Caremark Warning That Spooked Wall Street. CVS shares fell after the company gave preliminary 2027 profit guidance that disappointed investors; CFO Brian Newman called 2027 adjusted EPS of $8.44 merely "reasonable," matching — not exceeding — the average analyst estimate, and said Caremark is expected to lose members next year.
Caremark negotiates drug prices for employers, unions, and health plans. If its membership rolls shrink, CVS may have less bargaining power with drugmakers and less prescription volume flowing through its own pharmacies — putting pressure on future earnings.
The 340B Headwind Won't Go Away. Management noted that ongoing market dynamics in its 340B business — a federal program that lets certain hospitals buy drugs at steep discounts — will remain a headwind in 2027. Combined with the Caremark erosion, these pressures threaten CVS's Health Services segment, which generated $51.8 billion in Q2 revenue.
Cash Flow Strength Offers a Counterweight. Year-to-date cash flow from operations reached $10.6 billion, including roughly $6.3 billion in Q2 alone versus $1.9 billion a year ago.
CVS returned nearly $880 million in dividends during the quarter, extending a 56-year streak. That cash generation gives management room to absorb 2027 headwinds, but shareholders are clearly demanding proof that the turnaround extends beyond one good year.